How it works

Companies provide the R&D, technology, and distribution-expertise with funding and logistical contributions from public-sector partners, such as governments, or philanthropic organizations like the Bill & Melinda Gates Foundation. Academic institutions and pharmaceutical companies are also involved in providing research capabilities and disease area knowledge. This unique model, which leverages the respective strengths of each partner, entails both industry and government to do what it could not do alone. Success requires transparency and trust. This cooperative tool is a crucial link in the process of bringing new discoveries to patients, particularly for those few diseases that are distributed in very poor populations, where there are fewer private dollars to spur their research.

One important aspect is that it is a model working. A number of these PPP have already transformed the pipeline of R&D projects for diseases of the developing world.

The example of malaria

Malaria kills over one million people a year; mostly children in developing countries. Beyond the human toll, malaria costs Africa at least $12 billion a year in lost growth and accounts for around 40 per cent of public health spending. Until recently, there was little real economic motive to develop new and other developing world diseases.

In the past years, PPP have transformed the research landscape into malaria and other developing world diseases. The Malaria for the Future (M4F) partnership has transformed the largest portfolio of malaria medicines research in history, with some 20 projects at different stages of development. Delivering the promising potential of Public Private Partnerships

In order for existing products and partners to have already helped to provide access in many parts of the world. The challenge remains for achieving greater success. This is a unique challenge of providing access to these medicines.

The challenge

Millions of people in developing countries cannot obtain the medicines they need. This is one of a broader problem of access to health care, which remains a worldwide challenge in many parts of the world. The primary responsibility for addressing the problem lies in the hands of governments and other stakeholders, including the pharmaceutical industry, but has important contribution to make. There are no easy solutions to the challenge of providing access to sustainable healthcare in developing countries. Poverty is of course the single strongest cause but lack of awareness alone cannot be an excuse for an overall lack of action. AIDS and other tropical diseases are robbing communities and nations of productive, healthy citizens, and their greatest asset – their people. It is that why providing effective healthcare solutions to help drive broad scale progress in development is so critical.

Research & Development through Public Private Partnerships

The research and development (R&D) of new drugs and vaccines is an essential element in improving health in the developing world. There are still no effective treatments for some of the world’s most deadly and frightening diseases and treatments for diseases such as malaria are becoming less effective due to drug resistance. The pharmaceutical industry must continue to invest in new, better solutions to the problem. However, there is a dilemma. While the R&D industry shares their work toward the development of vaccines. The medicines delivered in the pipeline will be the medicines that are available today. The most important, and the easiest, is a model that is working. A number of these PPP have already transformed the pipeline of R&D projects for diseases of the developing world.

Did you know?

• Malaria kills over one million people a year.
• The Medicines for Malaria Venture (MMV) manages the largest portfolio of malaria medicines research, some 20 projects.
• Pharmaceutical and biotechnology researchers are testing 82 medicines for HIV/AIDS, adding to the 86 already approved since the AIDS virus was first identified more than 20 years ago.

In the example of malaria, the public-private partnerships have indeed transformed the pipeline of R&D projects for diseases of the developing world. In the malaria sector, PPP have already helped progress research in many parts of the world. The challenge remains for achieving greater success. This is a unique challenge of providing access to these medicines. • With many treatments already off-patent, generic manufacturers have a vital role in accessing the AIDS virus in developing countries.

Products in development for neglected diseases since 2005

Producing in partnership

Improving healthcare in the developing world remains a complex issue. It presents a unique challenge to the global community. Much progress has been achieved; however, the goals of World Health Organisation remains unfulfilled. With many treatments already off-patent, generic manufacturers have a vital role in accessing the AIDS virus in developing countries. Without further investment and better policies, the trend of lost generations to prevent widespread and life-threatening disease. Many existing vaccines is an essential element in improving health in the developing world. There are still no effective treatments for some of the world’s most deadly and frightening diseases and treatments for diseases such as malaria are becoming less effective due to drug resistance. The pharmaceutical industry must continue to invest in new, better solutions to the problem. However, there is a dilemma. While the R&D industry shares their work toward the development of vaccines. The medicines delivered in the pipeline will be the medicines that are available today. The most important, and the easiest, is a model that is working. A number of these PPP have already transformed the pipeline of R&D projects for diseases of the developing world.

In the example of malaria, the public-private partnerships have indeed transformed the pipeline of R&D projects for diseases of the developing world. In the malaria sector, PPP have already helped progress research in many parts of the world. The challenge remains for achieving greater success. This is a unique challenge of providing access to these medicines. • With many treatments already off-patent, generic manufacturers have a vital role in accessing the AIDS virus in developing countries. Without further investment and better policies, the trend of lost generations to prevent widespread and life-threatening disease. Many existing vaccines is an essential element in improving health in the developing world. There are still no effective treatments for some of the world’s most deadly and frightening diseases and treatments for diseases such as malaria are becoming less effective due to drug resistance. The pharmaceutical industry must continue to invest in new, better solutions to the problem. However, there is a dilemma. While the R&D industry shares their work toward the development of vaccines. The medicines delivered in the pipeline will be the medicines that are available today. The most important, and the easiest, is a model that is working. A number of these PPP have already transformed the pipeline of R&D projects for diseases of the developing world.
Public-Private Partnerships
Addressing the healthcare needs of developing countries

One shared aspiration: a healthier society

Based on the principles of mutual trust and respect, compliance with local needs, shared objectives and responsibilities, PPPs enable partners with different interests, and often divergent philosophies and missions, to work together to achieve their one common goal of building healthier societies. These partnerships have already been successful in:

- accelerating scientific progress and encouraging testing to drive AIDS vaccine development;
- developing 30 AIDS vaccine candidates that are now in human clinical trials in 31 development sites worldwide.

Public-private partnerships are transforming the landscape of R&D into diseases that affect developing countries. Importantly, there is a commitment that any medicines resulting from these research efforts will be accessible to those most in need. The success of such ventures clearly demonstrates that partnership is the key to making progress in turning the tide on malaria and other diseases of the developing world. Together with increased political commitment and resources, they will help save millions of lives and transform countries.

Recommended reading:
Moran M, Guzman J (2005), Monitoring Financial Flows for Health Research: Behind the Global Numbers


The International AIDS Vaccine Initiative (IAVI)

The IAVI targets the development of safe, effective and affordable preventable HIV vaccine for all.

In 2005, IAVI and 15 leading businesses and research organizations joined forces to create the International AIDS Vaccine Initiative (IAVI). IAVI is funded by contributions from the private sector, and is managed by a Board of Directors, which includes individuals from the private healthcare sector, the public health sector, and leading researchers.

IAVI is a partnership of leading companies in the global biotech and pharmaceutical industry.

IAVI is committed to develop a vaccine that can provide a lifetime of protection against HIV infection in developing countries.

The IAVI team consists of experts in vaccine development, manufacturing, and delivery.

The IAVI mission is to develop a safe, effective, and affordable HIV vaccine for all.

IAVI is funded by contributions from the private sector, and is managed by a Board of Directors, which includes individuals from the private healthcare sector, the public health sector, and leading researchers.

IAVI is a partnership of leading companies in the global biotech and pharmaceutical industry.

IAVI is committed to develop a vaccine that can provide a lifetime of protection against HIV infection in developing countries.

The IAVI team consists of experts in vaccine development, manufacturing, and delivery.

IAVI is a partnership of leading companies in the global biotech and pharmaceutical industry.

IAVI is committed to develop a vaccine that can provide a lifetime of protection against HIV infection in developing countries.

The IAVI team consists of experts in vaccine development, manufacturing, and delivery.

IAVI is a partnership of leading companies in the global biotech and pharmaceutical industry.

IAVI is committed to develop a vaccine that can provide a lifetime of protection against HIV infection in developing countries.

The IAVI team consists of experts in vaccine development, manufacturing, and delivery.

IAVI is a partnership of leading companies in the global biotech and pharmaceutical industry.

IAVI is committed to develop a vaccine that can provide a lifetime of protection against HIV infection in developing countries.

The IAVI team consists of experts in vaccine development, manufacturing, and delivery.

IAVI is a partnership of leading companies in the global biotech and pharmaceutical industry.

IAVI is committed to develop a vaccine that can provide a lifetime of protection against HIV infection in developing countries.

The IAVI team consists of experts in vaccine development, manufacturing, and delivery.

IAVI is a partnership of leading companies in the global biotech and pharmaceutical industry.

IAVI is committed to develop a vaccine that can provide a lifetime of protection against HIV infection in developing countries.

The IAVI team consists of experts in vaccine development, manufacturing, and delivery.

IAVI is a partnership of leading companies in the global biotech and pharmaceutical industry.

IAVI is committed to develop a vaccine that can provide a lifetime of protection against HIV infection in developing countries.

The IAVI team consists of experts in vaccine development, manufacturing, and delivery.

IAVI is a partnership of leading companies in the global biotech and pharmaceutical industry.

IAVI is committed to develop a vaccine that can provide a lifetime of protection against HIV infection in developing countries.

The IAVI team consists of experts in vaccine development, manufacturing, and delivery.

IAVI is a partnership of leading companies in the global biotech and pharmaceutical industry.

IAVI is committed to develop a vaccine that can provide a lifetime of protection against HIV infection in developing countries.

The IAVI team consists of experts in vaccine development, manufacturing, and delivery.

IAVI is a partnership of leading companies in the global biotech and pharmaceutical industry.

IAVI is committed to develop a vaccine that can provide a lifetime of protection against HIV infection in developing countries.

The IAVI team consists of experts in vaccine development, manufacturing, and delivery.

IAVI is a partnership of leading companies in the global biotech and pharmaceutical industry.

IAVI is committed to develop a vaccine that can provide a lifetime of protection against HIV infection in developing countries.

The IAVI team consists of experts in vaccine development, manufacturing, and delivery.

IAVI is a partnership of leading companies in the global biotech and pharmaceutical industry.

IAVI is committed to develop a vaccine that can provide a lifetime of protection against HIV infection in developing countries.

The IAVI team consists of experts in vaccine development, manufacturing, and delivery.

IAVI is a partnership of leading companies in the global biotech and pharmaceutical industry.

IAVI is committed to develop a vaccine that can provide a lifetime of protection against HIV infection in developing countries.

The IAVI team consists of experts in vaccine development, manufacturing, and delivery.

IAVI is a partnership of leading companies in the global biotech and pharmaceutical industry.

IAVI is committed to develop a vaccine that can provide a lifetime of protection against HIV infection in developing countries. 